Italy, Switzerland, Austria freeze sales of Novartis flu vaccines

October 24, 2012

Italian, Swiss and Austrian authorities on Wednesday halted the sale of flu vaccines made by Swiss pharmaceutical giant Novartis.

The Italian said it has banned the sale and use of several flu vaccines produced by Novartis pending tests into possible side-effects.

"The health ministry and the Italian medicines agency (AIFA) have decided to take the precaution of banning immediately the use of the vaccines" Aggripal, Fluad and Influpozzi, it said.

On the basis of information supplied by Novartis, AIFA "has decided that it is necessary to carry out further tests regarding the quality and the safety" of the vaccines, which "can produce collateral effects," the statement said.

In Switzerland, the national drug agency Swissmedic said it was ordering the "immediate halt of deliveries from Novartis," due to "possible ".

The alarm was raised after white particles were seen in syringes carrying the vaccines, Swissmedic said, stressing that they could be nothing more than little of the vaccine's components.

The Swiss decision affects some 160,000 , Swissmedic said, adding that it was unclear whether the problem affected vaccines already available in Switzerland.

The freeze on sales of the vaccines and their use was "a simple precaution" and those who had already been vaccinated for the flu "had nothing to worry about", it added.

In Austria, a spokeswoman for Novartis's Austrian subsidiary said that "further deliveries of the Novartis flu vaccines were stopped today (Wednesday)."

She added that the move was a precautionary measure following the moves by Italy and Switzerland.

stu-ide-nl/har

In their statement explaining the freeze on vaccine imports, Italian authorities said they had "decided that it is necessary to carry out further tests regarding the quality and the safety" of the vaccines.

burs/har

In Austria, a spokeswoman for Novartis's Austrian subsidiary said that "further deliveries of the Novartis flu vaccines were stopped today (Wednesday)."

She added that the move was a precautionary measure following similar decisions by Italy and Switzerland.

Explore further: Novartis starts testing swine flu vaccine

Related Stories

Novartis starts testing swine flu vaccine

August 5, 2009

(AP) -- Swiss drugmaker Novartis has begun injecting its swine flu vaccine into people in the company's first human tests, a spokesman said Wednesday. The vaccine is being tested in a yearlong trial of 6,000 people of all ...

WHO: Swine flu vaccine on track

August 6, 2009

(AP) -- Swine flu vaccine manufacturers are on track to start delivering the first batches of it in September, the World Health Organization said Thursday.

EU drug agency: License 2 swine flu vaccines

September 25, 2009

(AP) -- The European Union's drug regulator recommended Friday that two swine flu vaccines be licensed in the 27-nation bloc to ensure their availability before the start of the normal flu season.

Novartis denies problems with swine flu vaccine

October 26, 2009

Swiss pharmaceutical group Novartis on Monday denied that it faced hurdles in gaining regulatory approval in Switzerland for one of its swine flu vaccines because of possible bacterial contamination.

New development could increase flu vaccine supply

June 2, 2011

(Medical Xpress) -- Scientists from the U.S. Food and Drug Administration and the pharmaceutical company Novartis announced today in the journal Science Translational Medicine that they have developed a new adjuvant, or compound ...

Recommended for you

Non-addictive painkiller shows promise in animal trials

August 30, 2016

(HealthDay)—Preliminary research in monkeys suggests that a new medication might be able to provide pain relief similar to opioid drugs such as OxyContin, but without the same potential for addiction or serious side effects.

Mylan launching cheaper, generic version of EpiPen

August 29, 2016

The maker of EpiPens will start selling a cheaper, generic version of the emergency allergy shots as the furor over repeated U.S. price hikes continues—and looming competition threatens its near-monopoly.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.